Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 24.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 ISIN: BE0003818359 Ticker-Symbol: GXE 
Tradegate
23.10.19
17:26 Uhr
140,35 Euro
+1,00
+0,72 %
Branche
Biotechnologie
Aktienmarkt
BEL-20
AEX
1-Jahres-Chart
GALAPAGOS NV Chart 1 Jahr
5-Tage-Chart
GALAPAGOS NV 5-Tage-Chart
RealtimeGeldBriefZeit
139,05
139,70
23.10.
139,65
139,80
23.10.

Aktuelle News zur GALAPAGOS NV Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GALAPAGOS NV Aktien jetzt im kostenlosen Demokonto handeln!
MiGALAPAGOS NV - 6-K, Report of foreign issuer3
FrGalapagos Holding S.A. -- Moody's withdraws Galapagos' ratings11
16.10.HitGen teams up Galapagos to develop small molecule therapies10
14.10.Gilead-Galapagos Report Efficacy & Safety Results on RA Drug21
11.10.Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor23
11.10.Gilead, Galapagos share 52-week update on filgotinib11
11.10.The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout5
11.10.Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis4
11.10.Gilead and Galapagos' filgotinib shows durable effect in late-stage RA studies8
11.10.Galapagos NV: Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis582Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational...
► Artikel lesen
08.10.GALAPAGOS NV - 6-K, Report of foreign issuer4
07.10.Galapagos: A Rare De-Risked Biotech Opportunity11
07.10.Galapagos NV: Galapagos receives transparency notification from Wellington Management Group LLP226Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant...
► Artikel lesen
04.10.Galapagos (GLPG) Investor Presentation - Slideshow9
25.09.GALAPAGOS NV - 6-K, Report of foreign issuer9
24.09.Galapagos NV: Galapagos initiates Phase 1 trial for second Toledo compound313Second generation compound of novel target class with dual action in inflammatory disordersDiscovered and validated on Galapagos' target discovery platform Mechelen, Belgium; 24 September 2019...
► Artikel lesen
20.09.Galapagos NV: Invitation to the special and extraordinary shareholders' meetings337Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On...
► Artikel lesen
20.09.BRIEF-Galapagos Increases Share Capital Through Warrant Exercises12
19.09.GALAPAGOS NV - 6-K, Report of foreign issuer1
19.09.Galapagos NV: Galapagos increases share capital through warrant exercises238Mechelen, Belgium; 19 September 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos...
► Artikel lesen
Seite:  Weiter >>
142 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,3